Urologic Oncology Module for APPs (2017)

Member only benefit! In this era of increasing responsibility for primary care physicians and primary mid-level providers, it is important to recognize physical signs and symptoms that require additional evaluation and that may be a marker of urologic malignancy. Early identification of key signs and symptoms coupled with a thorough understanding of AUA practice guidelines, can lead to efficient medical evaluations and potentially to the detection of early stage urologic malignancies with a greater chance of cure. These issues are important in the detection of early prostate and bladder cancers.

Although the early detection of new tumors may be hampered by barriers to screening and inadequate diagnostic tools, the detection of recurrent tumors in patients with existing urologic malignancies may be more straightforward. The surveillance of such patients is critical to offer early salvage therapies that may still afford curative treatments. Many primary providers are unaware of the accepted surveillance practices of the major urologic malignancies, including prostate, bladder, and renal cell carcinomas.

This activity is designed to provide participants with an overview of the AUA guidelines for PSA screening and hematuria, and integrating the AUA into clinical practice, including specific time points and diagnostic tests for cancer surveillance of patients with urologic malignancies.

Target Audience

  • Physician Assistants
  • Advanced Practice Nurses

Learning Objectives

Upon completion of this activity participants should be able to:

  1. Identify male populations that require PSA screening, according to AUA guidelines.
  2. Formally diagnose hematuria in men and women.
  3. Interpret and explain the AUA guidelines for PSA screening and hematuria.
  4. Integrate AUA guidelines for PSA screening and hematuria into clinical practice.
  5. Define specific time points and diagnostic tests for cancer surveillance of patients with urologic malignancies.
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Non-Physician Participation
Course opens: 
05/15/2017
Course expires: 
05/15/2020
List Price:
$40.00
Rating: 
0

Faculty

The content of this enduring material was compiled by Cheryl Taylore Lee, MD and reviewed by Lou Koncz, PA-C from a presentation developed and previously presented by Sam S. Chang, MD.

Faculty Disclosures

Sam S. Chang, MD: Janssen: Consultant or Advisor, Meeting Participant or Lecturer; Astellas: Consultant or Advisor; Dendreon: Consultant or Advisor; NIH: Scientific Study or Trial; Cold Genesys, Inc.: Scientific Study or Trial; Cepheid: Scientific Study or Trial
Louis Koncz, PA-C: Nothing to disclose
Cheryl Taylore Lee, MD: Adolor: Scientific Study or Trial; Tengion, Inc.: Consultant or Advisor, Scientific Study or Trial; Endo Pharmaceuticals: Consultant or Advisor, Scientific Study or Trial; Photocure: Consultant or Advisor; CVI: Consultant or Advisor
 
Reviewer Disclosures
 
Timothy Charles Brand, MD: Nothing to disclose
Anne E. Calvaresi NP,CRNP: Nothing to disclose
Jody Donaldson (AUA Staff): Nothing to disclose
Todd James Doran, ED.D, PA-C, DFAAPA: Physician Assistant Education Association: Other
Shelby Englert (AUA Staff): Nothing to disclose
James R. Kovarik III, PA-C: Nothing to disclose
Thomas Patrick McBride ,PA-C: Nothing to disclose
Kenneth Mitchell, MPAS, PA-C: Nothing to disclose
Karen A. Poe NP: Nothing to disclose
Jody A. Purifoy, DNP, APRN, CNP: Nothing to disclose
Ashleigh Renitsky, PA-C: Nothing to disclose
Thomas Alan Rozanski ,MD: Nothing to disclose
Rochell L. Sasse ,MSN, RN, ACNP: Metronic: Consultant or Advisor
Heather Schultz, NP: SUNA: Meeting Participant or Lecturer
Daniel Thomas Vetrosky, PA-C: Nothing to disclose
Gwendolyn Brooke Zilinskas ,PA-C: Kimberly-Clark Corporation: Meeting Participant or Lecturer; Urology Association of Physician Assistants: Leadership Position, Meeting Participant or Lecturer
Tricia Zubert, NP: Nothing to disclose

Planner Disclosures

Education Council
Christopher Lee Amling, MD: Janssen: Meeting Participant or Lecturer
Gopal Badlani, MD: Lithotripsy Group: Piedmont stone & Physician Discovery: Investment Interest; Society of University Urologist: Leadership Position; NIDDK: Leadership Position
Timothy Charles Brand, MD: Nothing to disclose   
Peter Robert Carroll, MD: NIH: Scientific Study or Trial; Department of Defense: Scientific Study or Trial; Myriad Genetics: Scientific Study or Trial; Genomic Health: Scientific Study or Trial; Abbott Pharmaceuticals: Scientific Study or Trial; AUA Update: Leadership Position; Astra Zeneca: Meeting Participant or Lecturer; Genome Dx: Consultant or Advisor; Intuitive: Meeting Participant or Lecturer; Genomic Health: Consultant or Advisor; Takeda Pharmaceutical Company: Meeting Participant or Lecturer; Teva Pharmaceutical Industries: Meeting Participant or Lecturer; Janssen Pharmaceutical Companies: Meeting Participant or Lecturer; Intuitive Surgical Inc.: Meeting Participant or Lecturer
Sam S. Chang, MD: Janssen: Consultant or Advisor, Meeting Participant or Lecturer; Astellas: Consultant or Advisor; Dendreon: Consultant or Advisor; NIH: Scientific Study or Trial; Cold Genesys, Inc.: Scientific Study or Trial; Cepheid: Scientific Study or Trial
Pat Fox Fulgham, MD: Urology Clinics of North Texas: Investment Interest
Bruce R. Gilbert, MD, PhD: Bayer Healthcare Pharmaceuticals Inc.: Scientific Study or Trial; Auxilium: Scientific Study or Trial; Clarus Pharmaceutcals: Scientific Study or Trial; Eli Lilly: Scientific Study or Trial; Warner Chilcott: Scientific Study or Trial
Christina Hernandez (AUA Staff): Nothing to disclose        
Douglas A. Husmann, MD: Nothing to disclose
Wes Kassouf, MD: Nothing to disclose
Louis Koncz, PA-C: Nothing to disclose        
Cheryl Taylore Lee, MD: Adolor: Scientific Study or Trial; Tengion, Inc.: Consultant or Advisor, Scientific Study or Trial; Endo Pharmaceuticals: Consultant or Advisor, Scientific Study or Trial; Photocure: Consultant or Advisor; CVI: Consultant or Advisor
Thomas Sean Lendvay, MD: Spi Surgical Inc.: Consultant or Advisor, Owner, Product Development; MIMIC Technologies Inc.: Other
Vinata B. Lokeshwar, PhD: Nothing to disclose       
Elspeth Marguerita McDougall, MD: Nothing to disclose  
John Patrick Mulhall, MD: Association of Peyronie's Disease Advocates (APDA): Leadership Position; Pfizer: Scientific Study or Trial; Vivus: Consultant or Advisor, Scientific Study or Trial; Nexmed: Consultant or Advisor; Absorption Pharmaceuticals: Consultant or Advisor; AMS: Consultant or Advisor, Scientific Study or Trial; Meda: Consultant or Advisor; Lilly: Consultant or Advisor; Alliance for Fertility Preservation: Leadership Position
J. Kellogg Parsons, MD: AMS: Meeting Participant or Lecturer; Sophiris: Consultant or Advisor; Watson: Consultant or Advisor
Lee Richstone, MD: Wundercare LLC            : Consultant or Advisor
Marianne D. Sadar, PhD: ESSA Pharma Inc.: Leadership Position, Consultant or Advisor, Investment Interest
Karl-Dietrich Sievert, MD, PhD: AMS: Meeting Participant or Lecturer; Karl Storz: Meeting Participant or Lecturer; Photocure: Scientific Study or Trial; Medtronics: Meeting Participant or Lecturer, Scientific Study or Trial; Allergen: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Neotract: Meeting Participant or Lecturer
Sheila Stark, PhD (AUA Staff): Nothing to disclose 
William Donald Steers, MD: National Institutes of Health: Consultant or Advisor, Meeting Participant or Lecturer; Allergan: Scientific Study or Trial; New England Research Institute (NERI): Consultant or Advisor, Scientific Study or Trial
Chandru P. Sundaram, MD: Cook Medical Inc.: Scientific Study or Trial; North Central Section of the AUA: Leadership Position; Journal of Endourology and Videourology: Leadership Position; Society of Urological Robotic Surgeons: Leadership Position
Ashutosh Kumar Tewari, MD: Intuitive Surgical: Scientific Study or Trial; Kalyani Prostate Cancer Institute: Leadership Position; Global Prostate Cancer Foundation: Leadership Position; Peter Georgescu Foundation Award: Leadership Position; Chris Lange Foundation: Other; Peter Kalikow Foundation: Other; Craig Effron Foundation: Other; Tim O'Neill Foundation: Other; Patent for a Catheter-less device and approach: Other; NIH RO1 Funding-PI: Other
Paul Jacob Turek, MD: MandalMed: Leadership Position; Medical Board of California: Consultant or Advisor; BioQuiddity, Inc.: Consultant or Advisor, Investment Interest; HealthLoop.com: Consultant or Advisor, Investment Interest; Doximity, Inc.: Consultant or Advisor, Investment Interest; Fertility Planit, Inc.: Consultant or Advisor, Investment Interest
Alan J. Wein, MD, PHD (HON): Allergan: Consultant or Advisor, Meeting Participant or Lecturer; Medtronic: Consultant or Advisor, Meeting Participant or Lecturer; Ferring Pharmaceuticals: Consultant or Advisor, Meeting Participant or Lecturer; Pfizer; Consultant or Advisor, Meeting Participant or Lecturer; Astellas: Consultant or Advisor, Meeting Participant or Lecturer; Merck: Consultant or Advisor; opko: Consultant or Advisor; theravida: Consultant or Advisor

APN/PA Education Committee
Jeffrey A. Albaugh, PhD, APRN-BC, CUCNS: Sexual Medicine Society of North America: Leadership Position, Meeting Participant or Lecturer; Society of Urologic Nurses & Associates: Leadership Position, Meeting Participant or Lecturer; Prostate Net: Meeting Participant or Lecturer; Jannetti Publications Inc.: Other; Actient Pharmaceuticals LLC.: Consultant or Advisor, Meeting Participant or Lecturer; Astellas Pharma: Consultant or Advisor; Medivation: Consultant or Advisor
Roxelyn Baumgartner, RN, APN-BC: Nothing to disclose   
Ashleigh Decker, PA-C: Nothing to disclose 
Todd James Doran, MS, PA-C: Urological Association of Physician Assistants: Leadership Position; Physician Assistant Education Association: Leadership Position
Susan M. Flick, CNP: Pfizer: Other
Peggy Francis, DNP, RN, MSN, CS, FNP-BC, CUNP: Warner Chilcott: Meeting Participant or Lecturer
Gina Fries, RPA-C: Astellas Pharma US: Scientific Study or Trial
Raymond Matthew Galocy, ANP-C: Nothing to disclose    
Michele Huebner, PA-C: Urological Association of Physician Assistants: Leadership Position
Louis Koncz, PA-C: Nothing to disclose        
Ralph Raphael Madeb, MD: Nothing to disclose     
Thomas P. McBride, PA-C:  Adirondack Society of Physician Assistants: Leadership Position, Meeting Participant or Lecturer; Dendreon Corporation: Investment Interest; SeekingAlpha.com: Health Publishing
Heather Schultz, NP: Nothing to disclose
Allen D. Seftel, MD: Auxilium: Consultant or Advisor, Scientific Study or Trial; Journal of Urology: Leadership Position; Abbott: Consultant or Advisor; Lilly: Consultant or Advisor, Scientific Study or Trial; Journal of Sexual Medicine: Leadership Position; American Geriatrics Society: Leadership Position; Urology Care Foundation: Leadership Position; Mid -Atlantic Section of AUA: Leadership Position; AUA NPP committee: Leadership Position; International Journal of Impotence Research: Leadership Position; Patient Pocket, LLC: Owner, Product Development.
Meredith Vaccaro (AUA Staff): Nothing to disclose

Method of Participation

Learners will participate in this interactive online educational activity by reading through slides and case studies, answering multiple choice questions, examining patient tools and resources and completing the posttest and evaluation. To claim CME credit for this enduring material, learners must complete the posttest, passing with 80% accuracy and submit the program evaluation.

Estimated time to complete this activity: 1.0 hour

Original Release Date: May, 2014
Review Date: April, 2017
Expiration Date: April, 2020

AUA Disclosure Policy

All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) participating in an educational activity provided by the AUA are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

Resolution of Identified Conflict of Interest

All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

  • Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
  • Limit content to evidence with no recommendations
  • Introduction of a debate format with an unbiased moderator (point-counterpoint)
  • Inclusion of moderated panel discussion
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
  • Divestiture of the relationship by faculty

Accreditation Statement

The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The American Urological Association designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

If you have already received credit for this course by attending it or watching it live you cannot receive additional credit.

Evidence Based Content

It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

Off-label or Unapproved Use of Drugs or Devices

It is the policy of the AUA to require the disclosure of all references to off-label or unapproved uses of drugs or devices prior to the presentation of educational content. The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the product prescribing information for full disclosure of approved uses.

Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

Reproduction Permission

Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.

AUA Privacy and Confidentiality Policy

www.auanet.org/education/confidentiality-statement.cfm

Contact Information

American Urological Association
Office of Education
1000 Corporate Blvd.
Linthicum, MD 21090

Toll Free (U.S. only): 1-866-RING AUA (1-866-746-4282)
Phone: 410-689-3700
Fax: 410-689-3800

CME Information

For all inquiries regarding CME credit email: cme@AUAnet.org

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Non-Physician Participation

Price

List Price:
$40.00
Please login or register to take this course.